
The European Commission has cleared AstraZeneca’s (AZ) proposed acquisition of rare disease specialist Alexion, initially announced in December 2020.
Last year, AZ revealed its plans to acquire Alexion for approximately US$39 billion, in a bid to establish a specialist rare disease pipeline in the process.
Alexion’s portfolio of rare disease medicationss includes Soliris (eculizumab), a first-in-class anti-complement component 5 (C5) monoclonal antibody, and Ultomiris (ravulizumab), a second-generation C5 monoclonal antibody.
In a statement, AZ stated the EC clearance marks an “important step” towards the completion of the proposed acquisition.
The proposed acquisition has already received complete clearances from regulatory authorities in the US, Japan, and other countries globally. However, clearance in the UK is still pending and remains a requirement to complete the deal.
“We are pleased to have secured clearance from the European Commission for the proposed acquisition of Alexion, a pioneer in the discovery and development of medicines for rare diseases,” said Marc Dunoyer, executive director and chief financial officer of AZ.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
OpenAI Board Denies Receiving Formal Bid from Elon Musk
Feb 12, 2025 by
CPI
Thomas Kauper, Former DOJ Antitrust Leader, Dies at 89
Feb 12, 2025 by
CPI
BlackRock’s Acquisition of Preqin Secures UK Regulatory Approval
Feb 12, 2025 by
CPI
NFL Sued Over Bluesky Ban by Fans Citing Antitrust Violations
Feb 12, 2025 by
CPI
Warburg Pincus Strikes $1 Billion Deal to Acquire Vermont Information Processing
Feb 12, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon